Company profile
Neutra Corp.
OTC: NTRR · Healthcare · Biotechnology
#1067 of 1,418 Healthcare companies by revenue26th-percentile growth
EA Score
——FH —DQ 17GM —SS 42
v0.1 · 25/100 weight · pillars only
↑ Altman-Z, 3-yr revenue growth · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$1.2M
Rev growth YoY (TTM)
+398.9%
Net income (FY)
-$561.4k
Employees
15
as of 2026-08-26
Market cap
$583.6k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$68.0k$68.0k2023
Net income-$561.4k-$561.4k2023
Operating income-$297.7k-$297.7k2023
Total assets$75.2k$75.2k2023
Liabilities$813.8k$813.8k2023
Equity-$773.8k-$773.8k2023
Revenue trend
FY2020 – FY2023 · USD
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Neutra Corp.’s revenue?
Neutra Corp. booked $68.0k in FY2023 revenue, contracting 26% year over year — slower than 74% of Healthcare companies we track, at a -825.7% net margin.
Peers · Healthcare
Oncotelic Therapeutics, Inc.46DMYND Life Sciences Inc.——Vivos Inc.48DAquarius Surgical Technologies Inc.——Inovio Pharmaceuticals, Inc.37DKali, Inc.——Neighbors
Harris →Key facts
CEOSydney Jim
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeOTC: NTRR
Employees15
IPO date2011-10-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.